←PAYSPaysignOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Paysign runs donor cards and copay help

Donor cards

pays plasma donors on prepaid cards

Copay help

pays a patient's share at the pharmacy

CSL Plasma

among its collector clients

Paysign loads donors' fees onto prepaid cards for plasma collectors. For drug makers it checks copay claims, pays the patient's share and bills the maker back.

The company · 2 · What exactly does it sell?

Drug makers now edge out plasma

Each $1 of sales, second quarter of 2026
52%46%2%
Copay help for drug makersPlasma donor cardsOther

The copay side more than doubled; the plasma side is losing centres.

The company · 3 · How does it make money?

Fees per card and per claim

$110Msales in the past year
21%operating profit per $1
113plasma centres leaving by year-end

Overhead grows far slower than sales, so each new dollar adds profit.

Is it a good business? · 4 · What gives it an edge?

Switching is a nuisance, not a wall

47.7%

of US plasma centres use it

$325M

client savings it claims, unverified

When collectors sell centres, the new owner can move them to another provider, though every donor then needs a new card.

Is it a good business? · 5 · What is the catch?

A far larger rival runs the same service

McKessonsaves patients about $10B a year
Onbeprivate, sells the same donor cards
Haemoneticsplasma software linked to its machines

Listed rivals: MCK · HAE

Paysign saves patients about $1B a year against McKesson's $10B.

Is it a good business? · 6 · What does its record show?

Sales more than tripled, profit widened

Sales, $M
29.5
38.0
47.3
58.4
82.0
109.8
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$29.5M → $110Msales, 2021 to the past year
Profit−9.3% → 21%operating profit per $1
Kept50% → 63%kept per $1 after serving it

The shift to drug makers lifted what it keeps per dollar.

Is it a good business? · 7 · How much room is there to grow?

Copay is the bigger pool

$23Bdrug makers spent on copay aid in 2023
About $115.2Ma year if every US plasma centre paid its rate
Nearly $1Bof copay aid Paysign handled in 2025

Nobody publishes what administrators earn on the copay pool, so its size in fees is unknown.

Is it a good business? · 8 · Who is in charge?

The co-founder runs it with a big stake

2006Mark Newcomer began running it
16.3%of the company he owns
24.5%owned by officers and directors

Insiders own a lot, though they have been selling.

The story right now · 9 · Why do drug makers pay copays?

Drug makers pay patients' share to keep them

$23Bcopay aid in 2023
85%growth in Paysign's drug-maker sales, first half

Expensive drugs often leave patients a large share to pay. Drug makers cover it and pay firms like Paysign to run it; a federal rule against plans that drain that aid could remove its main appeal.

The story right now · 10 · Why is plasma shrinking?

A big customer is moving 113 centres

  1. Collectors sell centresNew owners choose.
  2. 113 centres move awayBy year-end.
  3. About $11.3M a yearOf revenue leaving.
  4. Copay must make it upGrowing fast.

Paysign expects 445 to 450 centres at year-end, down from 562.

The story right now · 11 · What changed lately?

Sales up 43% as plasma centres leave

$30.8Mrevenue in the third quarter
23.8%operating profit per $1, from 7.3%
About $11.3Ma year of revenue leaving
29.3%share jump after second-quarter results

Solid quarter

The shares doubled, mostly as buyers paid more per dollar of sales.

The story right now · 12 · What is everyone arguing about?

A fast grower, or bad news in the notes?

Many investors think

A fast-growing healthcare payments company

We think

Real copay growth, already in the price

The centre losses and a failed software purchase sit in the notes. Against us: it keeps beating and raising forecasts.

The price and our view · 13 · What is a share worth?

The price sits above even our best case

$6.62what we think a share is worth
$6.62our value
Attractive
below $5.30
Neutral
Unattractive
above $7.94
$3.32gloomy: growth halves, less kept per $1
$6.62our estimate: experts' path, then slowing
$9.07sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · What if it all works?

As a bet on copay programmes, it is fragile

Priced for successthe kind of bet this is
0.8×if it works
44%kept if it fails

Multiples of the company's value when the bet was last struck, 1 Oct 2026.

The price already pays for copay success, and a little under half is left if the programmes stall.

The price and our view · 15 · How could we be wrong?

A rule could remove its appeal

A rule on copay aidBiggest

Its main pitch.

Plasma centres leavingShowing now

113 by year-end.

McKesson's sizeWatch

Ten times bigger.

Fees on copayUnknown

Not published.

Insiders are selling, and collectors can move centres when they sell them.

The price and our view · 16 · How will we know?

March brings the first 2027 forecast

Copay growth keeps paceGood sign
Plasma losses stop at 113Good sign
A copay rule is adoptedBad sign
MAR 202710

Fourth-quarter and full-year 2026 results, 10 March. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 17 · So, what do we think?

Fast copay growth, a shrinking plasma business

$6.62our value
Attractive
below $5.30
Neutral
Unattractive
above $7.94

UnattractiveHigh conviction

Paysign's copay side more than doubled with real profit. But a rule could remove its main appeal, a plasma customer is moving 113 centres away, and the price sits above even our sunny future.

↑ ↓ to move · C for contents